Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
https://doi.org/10.1186/2051-1426-3-S2-P202
© Dillman et al. 2015
Published: 4 November 2015
Keywords
Table 1
Stratification | Treatment | # of patients | Median survival in months | 3-year overall survival |
---|---|---|---|---|
Measurable | DC-TC | 8 | 17.6 | 33% |
Measurable | TC | 9 | 6.5 | 11% |
Non-Measurable | DC-TC | 10 | Not Reached | 56% |
Non-Measurable | TC | 15 | 31.3 | 33% |
Recurrent Stage III | DC-TC | 3 | Not Reached | 67% |
Recurrent Stage III | TC | 6 | 30.3 | 17% |
Stage IV | DC-TC | 15 | 40.4 | 60% |
Stage IV | TC | 18 | 16.9 | 28% |
Trial registration
ClinicalTrials.gov identifier NCT00436930.
Authors’ Affiliations
References
- Dillman R, Cornforth A, DePriest C, et al: Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized Phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012, 35: 641-649.PubMedView ArticleGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.